Drugs / vedolizumab-800CW
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04112212 | Nov 2020 → Oct 2022 | Crohn disease, ulcerative colitis | University Medical Center Groningen | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vedolizumab-800CW | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04112212 ↗ |
| Known as | vedo-800CW | “We aimed to visualise the macroscopic and microscopic distribution of intravenous injected fluorescently labelled vedolizumab, vedo-800CW, and identify its target cells using...” PMID 38580386 ↗ Aug 2024 |
| Action | Inhibit | “capable of blocking the migration of several immune cells across endothelium expressing MAdCAM-1” NCT04112212 ↗ |
| Modality | Monoclonal antibody | “Vedolizumab is a humanized monoclonal antibody against α4β7 integrin” NCT04112212 ↗ |
| Route | Intravenous | “First vedolizumab-800CW was administered intravenously” NCT04112212 ↗ |